RxDoctor Payments DataLook up a doctor →

Steven Sutherland, MD

Child & Adolescent Psychiatry · Charlotte, NCNPI 1720098213

Payments from drug & device makers

$168,917in general payments, 2019–2025

Across 655 payments — averaging $257.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$125K
  • Ironshore Pharmaceuticals Inc.$37K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Otsuka America Pharmaceutical, Inc.$849
  • AbbVie$649
  • Vanda Pharmaceuticals Inc.$434
  • plus $3K from 22 others

What the payments were for

  • Speaking & faculty fees$143,34885%
  • Travel & lodging$13,3868%
  • Food & beverage$12,1447%
  • Education$400%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$168,917 in reported general payments places this provider in the 95th percentile of 91 child & adolescent psychiatry providers in North Carolina.

See all child & adolescent psychiatry providers in North Carolina

Medicare billing

Part B allowed, 2024
$11,563
Medicare patients
31
Services billed
119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole18$25,122
VraylarCariprazine Hcl13$18,967
ClozarilClozapine13$15,517
FanaptIloperidone11$12,317
VyvanseLisdexamfetamine Dimesylate25$9,655
Aripiprazole17$8,169
Perphenazine28$6,364
Duloxetine Hcl81$3,349
Lisdexamfetamine Dimesylate13$2,993
Quetiapine Fumarate ErQuetiapine Fumarate19$2,409
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine69$2,132
Clonazepam116$1,418
Quetiapine Fumarate56$1,327
Desvenlafaxine Succinate ErDesvenlafaxine Succinate26$1,326
Clomipramine Hcl13$1,125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$849$25,12218 claims
AbbVieVraylar$649$18,96713 claims
Vanda Pharmaceuticals Inc.Fanapt$434$12,31711 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$245$9,65525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 91 child & adolescent psychiatry providers in North Carolina.

Other child & adolescent psychiatry in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →